Difference between revisions of "National Resilience"
(stub) |
(some expand) |
||
| Line 3: | Line 3: | ||
|sourcewatch= | |sourcewatch= | ||
|constitutes= | |constitutes= | ||
| − | |logo= | + | |logo=National Resilience biotechnologies logo.png |
| + | |titular_logo=1 | ||
|start=2020 | |start=2020 | ||
|description= | |description= | ||
| Line 15: | Line 16: | ||
==Activities== | ==Activities== | ||
| − | In March 2023, Resilience Resilience received a $410 million loan from [[DoD|Defense | + | National Resilience was founded in [[2020]], with $800 million in capital.<ref name=fiercepharma>https://www.fiercepharma.com/manufacturing/manufacturer-national-resilience-helmed-by-former-novavax-chief-snags-sanofi</ref> |
| + | |||
| + | In March 2021, Resilience acquired a former [[Sanofi]] manufacturing plant in [[Boston]]. The company established a "network of high-tech, end-to-end manufacturing solutions" to make current and future drugs "quickly, safely, and at scale," Resilience said in a PR-release.<ref name=fiercepharma/> | ||
| + | |||
| + | In 2021, Resilience and [[Moderna]] announced an agreement to manufacture "drug substance" for the [[Moderna COVID-19 vaccine]]. Under the terms of the multi-year agreement, Resilience will produce [[mRNA]] for the Moderna COVID-19 vaccine at its facility in Mississauga, [[Ontario]] in [[Canada]], for distribution worldwide.<ref>https://www.businesswire.com/news/home/20210908005677/en/Resilience-to-Manufacture-mRNA-for-Moderna%E2%80%99s-COVID-19-Vaccine</ref> | ||
| + | |||
| + | In March 2023, Resilience Resilience received a $410 million loan from [[DoD|Department of Defense]].<ref>https://www.fiercepharma.com/manufacturing/white-house-eyes-biomanufacturing-boost-local-producer-national-resilience-adds-410m</ref> | ||
| + | |||
| + | In partnership with the Department of Defense, Resilience manages the DOD Advanced Development and Manufacturing (ADM) facility in [[Alachua, Florida]] as a contractor-owned, contractor-operated end-to-end biomanufacturing facility.<ref>https://resilience.com/engage/govt</ref> | ||
==People== | ==People== | ||
| − | Board as of March 2024.<ref>https://resilience.com/meet/team/</ref> Board members include people from the [[Gates Foundation]] and the [[CIA]] | + | Board as of March 2024.<ref>https://resilience.com/meet/team/</ref> Board members include people from the [[Gates Foundation]] and the [[CIA]]. |
| + | |||
| + | Board member [[Susan Desmond-Hellmann]] was former CEO of the [[Gates Foundation]]. | ||
| + | |||
| + | [[Chris Darby]] is head of the [[CIA]]'s [[In-Q-Tel ]]. | ||
| + | [[Rahul Singhvi]] was previously was President and CEO of [[Novavax]] and the [[vaccine]] department at [[Takeda Pharmaceuticals]].<ref>https://aibn.uq.edu.au/dr-rahul-singhvi</ref> | ||
| + | The company also counts former [[FDA]] commissioner [[Scott Gottlieb]] among its founding board of directors.<ref name=fiercepharma/> | ||
{{SMWDocs}} | {{SMWDocs}} | ||
Latest revision as of 23:21, 6 March 2024
 National Resilience    | |
|---|---|
 | |
| Formation | 2020 |
| Headquarters | San Diego, California, USA |
| Membership | • Robert Nelsen • Patrick Y. Yang • Drew Oetting • Rahul Singhvi • Frances Arnold • George Barrett • Mitchell E. Daniels Jr • Chris Darby • Susan Desmond-Hellmann • Kaye Foster • Scott Gottlieb • Joseph Robert Kerrey • Denice Torres |
National Resilience, Inc is a "technology-focused biomanufacturing company dedicated to broadening access to complex medicines".[1]
Contents
Activities
National Resilience was founded in 2020, with $800 million in capital.[2]
In March 2021, Resilience acquired a former Sanofi manufacturing plant in Boston. The company established a "network of high-tech, end-to-end manufacturing solutions" to make current and future drugs "quickly, safely, and at scale," Resilience said in a PR-release.[2]
In 2021, Resilience and Moderna announced an agreement to manufacture "drug substance" for the Moderna COVID-19 vaccine. Under the terms of the multi-year agreement, Resilience will produce mRNA for the Moderna COVID-19 vaccine at its facility in Mississauga, Ontario in Canada, for distribution worldwide.[3]
In March 2023, Resilience Resilience received a $410 million loan from Department of Defense.[4]
In partnership with the Department of Defense, Resilience manages the DOD Advanced Development and Manufacturing (ADM) facility in Alachua, Florida as a contractor-owned, contractor-operated end-to-end biomanufacturing facility.[5]
People
Board as of March 2024.[6] Board members include people from the Gates Foundation and the CIA.
Board member Susan Desmond-Hellmann was former CEO of the Gates Foundation.
Chris Darby is head of the CIA's In-Q-Tel .
Rahul Singhvi was previously was President and CEO of Novavax and the vaccine department at Takeda Pharmaceuticals.[7]
The company also counts former FDA commissioner Scott Gottlieb among its founding board of directors.[2]
Known member
1 of the 13 of the members already have pages here:
| Member | Description |
|---|---|
| Scott Gottlieb | Food and Drug Administration leader, then over to Pfizer. |
References
- ↑ https://resilience.com/
- ↑ a b c https://www.fiercepharma.com/manufacturing/manufacturer-national-resilience-helmed-by-former-novavax-chief-snags-sanofi
- ↑ https://www.businesswire.com/news/home/20210908005677/en/Resilience-to-Manufacture-mRNA-for-Moderna%E2%80%99s-COVID-19-Vaccine
- ↑ https://www.fiercepharma.com/manufacturing/white-house-eyes-biomanufacturing-boost-local-producer-national-resilience-adds-410m
- ↑ https://resilience.com/engage/govt
- ↑ https://resilience.com/meet/team/
- ↑ https://aibn.uq.edu.au/dr-rahul-singhvi
